Antibody-Drug Conjugates and Linker Engineering 4

• 5631 TCX-201, a novel ADC targeting a specific tumor-associated carbohydrate antigen (TACA) with excellent preclinical efficacy, PK and safety profile in solid tumor models Matthias Ocker, Francesco Muraca, Stephan Grunwald, Wiebke Winkler, Karla E. G. Soto, Carolin Lange, Jean Engela, Peter Sondermann
• 5632 · PDF Enhancing dual-payload ADC discovery projects by overcoming heterogeneity and resistance through dual-payload innovation Ying Meng, Lili Chai, Wei Liu, Xue Yang, Min Kang, Rui Song, Zhengtai Li, Yan Zhang, Zhiwei Bao, Ying Bi, Yixiao Zhao, Wange Fan, Xiao Li, Li Li, Tiejun Bing
• 5633 YB-811, a novel antibody drug conjugate targeting the tumor-selective human neuronal pentraxin receptor shows pronounced efficacy in experimental tumor models Peter Schiemann, Michel Janicot, Gunther Wennemuth, Mykola Lyndin
• 5634 KY102, a novel Glypican 3-targeting nanobody drug conjugate bearing a topoisomerase 1 inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models Haikun Shi
• 5635 · PDF Rational design of a bispecific ADC targeting ITGB4 and TROP2 for co-expressing solid tumors Mi Young Cha, Jiyoung Lee, Hyunkyung Yu, Hyunuk Kim, Youngeun Ha, Bu-Nam Jeon, Seungmin Byun, Kitae Park, Mira Kim, Han-Sol Kim, Wuhwui An, Hyonam Kim, Sang-Gyun Kim, Hansoo Park
• 5636 · PDF Preclinical evaluation of LM-338: An innovative anti-STn antibody drug conjugate for solid tumors Jin Li, Junwei Yang, Yuan Li, Te Du, Xia Qin, Da Fei, Lei Shi, Wei Cao
• 5637 A novel EGFR and B7H3 dual-targeted antibody-drug conjugate (ADC) for the treatment of solid tumors Mingkun Zhang, Xuguo Zhu, Jun Wang, Jing Zhao
• 5638 · PDF A first-in-class photo-responsive EGFR-ADC drives ROS-mediated, energy-dependent tumor eradication in preclinical models Wentao Shang, Hua Shang, Josie Cai, Vicky Qin, Lyan Chen, Xiaobo Zhang
• 5639 HDP-103, a PSMA targeting amanitin-based ADC, is efficacious even in difficult to treat patient derived xenograft models with heterogenous PSMA expression Kristin Decker, Christian Orlik, Irina Dranova, Anikó Palfi, Torsten Hechler, Andreas Pahl, Michael Kulke
• 5640 · PDF ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer Sam Lawn, Andrea Hernández Rojas, Vidhi Khanna, Jodi Wong, Ambroise Wu, Matthew Bonderud, Victoria Harman-McKenna, Taixiang Wang, Allysha Bissessur, Kaylee Wu, Manuel Lasalle, Vincent Fung, Chayne L. Piscitelli, Dunja Urosev, Luying Yang, Graham A. E. Garnett, Raffaele Colombo, Jamie R. Rich, Stuart D. Barnscher
• 5641 BCG037, a first-in-class anti-human ALPP/ALPG therapeutic ADC that inhibits tumor growth in pancreatic cancer and gastric cancer PDX models Yong Xie, Peiran Li, Ying Zhu, Yanan Guo
• 5642 · PDF BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors Guan Wang, Peiran Li, Ying Zhu, Yanan Guo
• 5643 Preclinical characterization of RC118 ADC and identification of its differential binding pattern relative to other anti-CLDN18.2 antibodies Lili Wang, Xiaoping Zhang, Mingyang Li, Xiao Wang, Yidan Xu, Xiaoli He, Shengle Ji, Shuya Ji, Shifu Wang, Yinghao Xin, Fanxue Bu, Yuelei Shen, Jianmin Fang, Yuanhao Li
• 5644 DA-3501 (AT-211): Evaluation of immune-mediated antitumor activity and combination immunotherapy potential of a site-specific CLDN18.2-targeting antibody-drug conjugate (ADC) Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 5645 · PDF NW006-296, a novel ROR1 targeting ADC, demonstrates compelling anti-tumor efficacy in preclinical studies Zhaoyu Gou, Liqian Zhou, Li Liu, Zikuo Zhang, Gang Liu, Yiran Wu, Dan Mi, Jiabao Liu, Yaolan Dai, Zhijian Li, Wenting Luo, Bin Liu, Desi Pan, Zhigang Guo
• 5647 GS24-B057, a potential best-in-class Nectin-4- and Trop-2-directed bispecific ADC, for the treatment of urothelial carcinoma and other solid tumors Meihan Li, Fu Li, Qiuru Che, Xiaojing Huang, Dongxia Chu, Qiyang Zhang, Nan Li, Qingjuan Ma, Weiming He, Wenqiang Zhai, Yihui Lin, Xiaozhen Wang, Fanglong Yang, Siqing Wang, Lei Jin, John L. Xu
• 5648 · PDF Preclinical efficacy and safety of KIVU-305, a novel CEACAM5-targeting antibody-drug conjugate (ADC) for colorectal cancer (CRC) Ann MacLaren, Natasja N. Viller, Tessie Ng, Liangyi Zhang, Xiaoyue Jiang, Mohit Trikha
• 5649 · PDF KIVU-107: A clinical-stage, best-in-class PTK7 antibody-drug conjugate (ADC) with favorable PK and an improved tolerability profile Natasja N. Viller, Liangyi Zhang, Xiaoyue Jiang, Ann MacLaren, Mohit Trikha
• 5650 · PDF Preclinical development of LUA006: A bispecific EGFR/B7-H3 ADC with dual payloads to address tumor heterogeneity and resistance Shaojuan Zhao, Ling Zhang, Ying Huang, Qian Dong, Xiaofan Gu, Guoshun Tian, Xiaoman Li, Fanrui Meng, Wei Zheng, Xiaoshuang Yan, Xinmei Wang, Yazhi Yuan, Shuyong Zhao, Ken Qin, Yang Yang, Hua Ying, Weikang Tao
• 5651 Preclinical development of LUA005: A differentiated bivalent EGFR/cMET bispecific ADC displays strong anti-cancer efficacy and a wider therapeutic window Lei Han, Ken Qin, Ying huang, Xi Xiao, Zhebin Zhang, Wei Wang, Wei Zheng, Hai Wu, Xiaoshuang Yan, Dongdong Wu, Shuyong Zhao, Ling Zhang, Yang Yang, Hua Ying, Weikang Tao
• 5652 Preclinical development of LUA011, a novel CDH17/cMET bispecific ADC with enhanced antitumor efficacy and mitigated gastrointestinal toxicity Guoyin Huang, Ken Qin, Man Wu, Lei Han, Ying Huang, Wei Zheng, Xiaoshuang Yan, luchan deng, Hai Wu, Wenshu Huang, Shuyong Zhao, Ling Zhang, Yang Yang, Hua Ying, Weikang Tao
• 5653 · PDF Preclinical characterization of LUA004, a novel 5T4-targeting ADC with improved therapeutic window Jinpeng Pei, Shaojuan Zhao, Ying Huang, Junfei Wang, Wei Zheng, Hai Wu, Jie Chen, Ke Li, Xinmei Wang, Shuyong Zhao, Ling Zhang, Yang Yang, Daqing Sun, Hua Ying, Weikang Tao
• 5654 · PDF Novel ALDC and ADC with TMEAlinker and eribulin payload demonstrate excellent safety and efficacy in preclinical evaluation Tao Chen, Cheng Liu, Yuan Liu
• 5655 · PDF YL252: A dual-functional PD-L1/VEGF-targeting ADC integrating immunotherapy, anti-angiogenesis, and cytotoxicity Wei Lian, Xinzhen Shi, Qing Zong, Hanwen Deng, Chun Deng, Tao Wang, Fang Xu, Shuaikun Wang, Tongtong Xue, Jiaqiang Cai
• 5656 Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage Victoria Juskaite, Tom Clough, Ellen Watts, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Alexa Kennedy, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink, Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones
• 5657 A novel bispecific ADC to treat solid tumors by removing immunosuppression in the tumor microenvironment Shiva Bhowmik, William Brady
• 5659 · PDF Unveiling the PanCancer potential of dual-targeting uPAR-directed ADCs across cancers Virginia Metrangolo, Lars Henning Engelholm, Henrik Jessen Jürgensen, Sine Rosendal Syversen, Michaela Hansen Blomquist

在完整检索应用中浏览本分会场 →